Herceptin + rGel

Herceptin + rGel (also referred to as Herceptin/rGel or trastuzumab-gelonin) is an experimental bivalent immunotoxin conjugate consisting of the humanized anti-HER2 monoclonal antibody Herceptin (trastuzumab) chemically conjugated to recombinant gelonin (rGel), a ribosome-inactivating plant toxin. Developed primarily as an academic research compound by investigators at the University of Texas MD Anderson Cancer Center, this immunotoxin is designed to target and destroy HER2/neu-overexpressing cancer cells, such as those in HER2-positive breast and ovarian cancers. Upon binding to HER2, the conjugate is internalized, releasing the rGel payload into the cytoplasm where it enzymatically inhibits protein synthesis, leading to cell death. In preclinical studies, Herceptin + rGel demonstrated potent in vitro and in vivo antitumor activity, including efficacy against Herceptin-resistant cancer models.

Other names

Herceptin/rGelHerceptin/rGel conjugateTmab-rGeltrastuzumab-gelonintrastuzumab-gelonin conjugatetrastuzumab-rGeltrastuzumab-rGel conjugate